AG
CNCE

Artal Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Artal Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-573,062
Closed -$3.84M – 145
2022
Q3 		$3.84M Buy
+573,062
New +$3.47M 0.16% 68

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group's CNCE Position: Q4 2022 in Review

Artal Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 573,062 shares — an estimated $3.84M sold.

Artal Group first reported a position in CNCE in Q3 2022 and held it in 1 quarter. The position peaked at $3.84M in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • Artal Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Artal Group sold 573,062 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $3.84M.
  • Artal Group first reported a position in Concert Pharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Artal Group's Concert Pharmaceuticals, Inc. position peaked at $3.84M in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.